Development of a Potent and Selective G2A (GPR132) Agonist.
Hernandez-Olmos V, Heering J, Marinescu B, Schermeng T, Ivanov VV, Moroz YS, Nevermann S, Mathes M, Ehrler JHM, Alnouri MW, Wolf M, Haydo AS, Schmachtel T, Zaliani A, Höfner G, Kaiser A, Schubert-Zsilavecz M, Beck-Sickinger AG, Offermanns S, Gribbon P, Rieger MA, Merk D, Sisignano M, Steinhilber D, Proschak E.
Hernandez-Olmos V, et al. Among authors: moroz ys.
J Med Chem. 2024 Jul 11;67(13):10567-10588. doi: 10.1021/acs.jmedchem.3c02164. Epub 2024 Jun 25.
J Med Chem. 2024.
PMID: 38917049